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ABSTRACT
Aim: To conduct a meta-analysis of randomised clinical
trials (RCTs) in order to evaluate the development of
conjunctival hyperaemia after the use of latanoprost
versus travoprost and bimatoprost, in patients with ocular
hypertension or glaucoma.
Methods: In order to identify the potentially relevant
RCTs, a systematic literature retrieval was conducted in
Medline, Embase and Cochrane Controlled Trials Register
(1995–April 2007) databases The outcome measure was
the appearance of conjunctival hyperaemia during the
study. Statistical analyses included the calculation of odds
ratio (OR) and its respective confidence interval, along
with intertrial statistical heterogeneity. Publication bias
was evaluated through a funnel plot, and a sensitivity
analysis was also performed.
Results: In total, 13 RCTs involving 2222 patients with
ocular hypertension or glaucoma were included, five
comparing latanoprost versus travoprost, seven compar-
ing latanoprost versus bimatoprost and one comparing
latanoprost versus travoprost and bimatoprost. The
combined results showed that latanoprost produced
lower occurrence of conjunctival hyperaemia than both
travoprost (OR=0.51; 95% CI 0.39 to 0.67, p,0.0001)
and bimatoprost (OR=0.32; 95% CI 0.24 to 0.42,
p,0.0001). No significant heterogeneity was found
between the included RCTs. There was no evidence of
publication bias. In the sensitivity analysis performed,
none of the clinical trials included in this meta-analysis
has an important impact in the global estimation of OR.
Conclusions: According to available data, the use of
latanoprost is associated with a lower incidence of
conjunctival hyperaemia when compared with travoprost
and bimatoprost in the treatment of patients with ocular
hypertension or glaucoma.
The estimated prevalence of glaucoma is 2% in the
general population, 3% in people over 50, 5.7% in
subjects 73 and 74 years old and 23.2% in those
aged 75 years and older. This number is expected
to increase in the future, given the progressive
ageing of the population.
1–3
For patients with ocular hypertension or open-
angle glaucoma, drug therapy focuses on reducing
intraocular pressure (IOP) levels in order to delay
or prevent the progression of ocular hypertension
to glaucoma, and to slow disease progression in
glaucoma patients.
45In both cases, patients require
lifelong treatment and follow-up care to preserve
vision, so it is essential long-term patient compli-
ance and medication persistency, because those
who do not continue therapy risk developing
elevated IOP levels and, over time, progressing to
blindness.
6
Compliance and persistency depends on many
factors, including patient satisfaction with medica-
tion, medication costs, ease of medication admin-
istration and patient understanding of the
importance of taking their medication over the
long term, although one of the most important
factors is local and systemic side effects.
7
Currently, first-line treatment usually consists
of monotherapy with a topical hypotensive drug.
Although ophthalmologists traditionally have pre-
scribed beta-blockers as first-line ocular hypoten-
sive therapy, due to the possibility of producing
systemic side effects, other therapeutic options are
currently preferred, with prostaglandin analogues
being one of the most widely used.
8
Topical prostaglandins such as latanoprost,
bimatoprost and travoprost are similar in that
they require once-daily instillation, produce few
systemic side effects and reduce IOP levels simi-
larly.
9–11 However, some prostaglandin-treated
patients experience conjunctival hyperaemia,
12
and this condition is of concern because this side
effect may have a negative affect on whether the
patient takes the drug as directed (compliance)
and/or continues to use the drug over time
(persistency).
Although a lower rate of conjunctival hyperae-
mia has been reported with latanoprost in contrast
to bimatoprost and travoprost,
13 no systematic
review and meta-analysis has examined this issue.
Therefore, the aim of this work was to conduct a
meta-analysis of RCTs comparing latanoprost
against bimatoprost and travoprost, either together
or in separated studies, in patients with ocular
hypertension and/or glaucoma.
METHODS
Search strategy
Reports of RCTs comparing latanoprost, bimato-
prost and travoprost were identified through a
systematic search. A computerised literature search
was conducted in Medline, Embase and Cochrane
Controlled Trials Register databases from 1995 to
April 2007 for relevant articles in English.
We used the Medical Subject Heading and the
following key words: glaucoma, ocular hyperten-
sion, randomisation, trial, latanoprost, bimato-
prost, travoprost and conjunctival/ocular
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searched for relevant titles.
Study selection
Two reviewers independently conducted the literature search
and extraction of relevant articles. The title and abstract of
potentially relevant studies and review articles were screened for
appropriateness before retrieval of the full articles.
The following selection criteria were used to identify
published studies for inclusion in this meta-analysis: (a) study
design—RCTs in adults (age.18 years); (b) population—
patients with ocular hypertension and/or glaucoma; (c) inter-
vention—latanoprost versus other prostaglandins analogues
(bimatoprost or travoprost) as monotherapy; (d) outcome
variable—conjunctival hyperaemia. These articles were written
in English. Abstracts from conferences without raw data
available for retrieval and duplicate publications were excluded.
Data extraction
Two reviewers performed separately the data extraction and
methodological quality assessment of trials that were included.
The reviewers were blinded for the names of the authors and
their institution, the names of the journals, sources of funding
and acknowledgments. Any disagreements between the
reviewers were resolved by discussion to reach consensus. A
third reviewer was involved when required.
A customised form was created to record the information of
selected articles: year of publication, information of study
design (double-blind, parallel or crossover), length of study,
number of subjects, age, sex, type of glaucoma and proportion
of conjunctival hyperaemia.
The primary outcomes measure was the incidence of
conjunctival hyperaemia over treatment visits. The reason for
exclusion was recorded on a standard form. Excluded publica-
tions were reassessed to ensure that all eligible publications
were included.
Figure 1 Selection algorithm for the
randomised controlled trials (RCTs)
included in this meta-analysis.
Figure 2 Global and partial statistical data of clinical trials comparing latanoprost and travoprost.
Clinical science
Br J Ophthalmol 2009;93:316–321. doi:10.1136/bjo.2007.135111 317Assessment of study quality
Two reviewers independently rated study quality using the
Jadad instrument for the assessment of the quality of trials
reports.
14 This instrument is a point scale ranging from 0 to 8,
with points derived from the description of randomisation,
blinding, inclusion and exclusion criteria, withdrawals and
method of assessing adverse events.
Statistical methods and assessment of heterogeneity
The statistical analysis was carried out by Comprehensive
Meta-Analysis software version 2.2 (Biostat, Englewood Cliffs,
New Jersey) (http://www.meta-analysis.com).
For dichotomous outcomes, we calculated a pooled odds ratio
(OR) and 95% CIs. The OR was defined as the odds of an
outcome in those who received latanoprost therapy compared
with the odds in those who received bimatoprost or travoprost.
The ORs of different RCTs were combined by using the fixed
effects model of Mantel and Haenszel
15 and the random effects
model of Der Simonian and Laird.
16
Intertrial statistical heterogeneity was explored using the
Cochran Q test with calculated I
2,indicating the percentage of
the total variability in effect estimates among trials that is due
to heterogeneity rather than to chance.
17 I
2 values of 50% or
more indicate a substantial level of heterogeneity. Publication
bias was assessed by visually inspecting a funnel plot.
All p values were two-sided with statistical significance set at
an a level of 0.05. We followed the Quality of Reporting Meta-
analysis guidelines for reporting and discussing these meta-
analytical results.
18
To exclude the possibility that any one study was exerting
excessive influence on the results, we conducted a sensitivity
analysis by systematically excluding each study at a time and
then rerunning the analysis to assess the change in ORs.
RESULTS
Literature search
There were 31 articles relevant to the search term. A total of 18
potential RCTs of latanoprost versus other prostaglandin
analogues were identified through the literature search,
19–36 five
comparing latanoprost vs travoprost, seven comparing latano-
prost vs bimatoprost and one comparing latanoprost vs
bimatoprost and travoprost.
Finally, 13 articles involving 2222 patients with ocular
hypertension or glaucoma were included in this meta-analy-
sis.
24–36 The algorithm flow chart for the selection of RCTs to be
included in our analysis is shown in fig 1.
Figure 3 Global and partial statistical data of clinical trials comparing latanoprost and bimatoprost.
Figure 4 Funnel plot of clinical trials included in the meta-analysis
comparing latanoprost vs travoprost.
Figure 5 Funnel plot of clinical trials included in the meta-analysis
comparing latanoprots vs bimatoprost.
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Table 1 shows the characteristics of the RTCs that were
included in this meta-analysis. Overall, 2222 patients were
evaluated for an average period of follow-up of 4.1 months
(min=2 weeks; max=9 months). Nine hundred and thirty-
one patients were treated with latanoprost, 624 with bimato-
prost and 667 with travoprost.
Patients’ ages ranged from 58 to 73 years with a mean of 65;
41.4% were men, 1364 patients (61.4%) suffered from open-
angle glaucoma, 678 (30. 5%) from ocular hypertension and 180
(8.1%) from another type of glaucoma (chronic angle-closure
glaucoma, exfoliative glaucoma and pigmentary glaucoma).
The proportion of patients treated with latanoprost who
developed conjunctival hyperaemia was 16.5% (min=3.3%;
max=47.1%), in the bimatoprost group 40.2% (min=14.3%;
max=68.6%) and in the travoprost group 33% (min=6.2%;
max=58%).
Hyperaemia outcome
The combined results of different clinical trials suggested that
the use of latanoprost 0.005% caused a lower percentage of
appearance of conjunctival hyperaemia compared with travo-
prost 0.004% (OR=0.51; 95% CI 0.39 to 0.67, p,0.00001). No
significant heterogeneity was found between included clinical
trials (Q=3.98; p=0.56) (fig 2).
Moreover, the results of this meta-analysis also showed that
the utilisation of latanoprost 0.005% is associated with a lower
development of conjunctival hyperaemia when compared with
bimatoprost 0.003% (OR=0.32; 95% CI 0.24 to 0.42,
p,0.00001). Heterogeneity between included clinical trials did
not show any significance (Q=4.18; p=0.75) (fig 3).
Sensitivity analysis
In order to analyse the consistency and robustness of the
results, a sensitivity analysis was performed (table 2). First, the
results obtained were compared using the fixed and random
models. Changing the model from fixed to random effects did
not change the results of our meta-analysis.
Second, in order to assess the influence of each individual
clinical trial included in the meta-analysis, each study was
excluded at a time and the analysis performed again to
determine the change in the OR. The punctual estimators for
OR vary between 0.46 and 0.54 in the latanoprost–travoprost
analysis, and between 0.29 and 0.34 in the latanoprost–
bimatoprost analysis after excluding one by one each original
clinical trial. None of the clinical trials included in this meta-
analysis had an important impact in the global estimation of the
OR.
Publication bias
An analysis of publication bias was conducted. For each separate
analysis (latanoprost–travoprost and latanoprost–bimatoprost),
based on a visual analysis of the funnel plots, no evidence of
publication bias was found (figs 4, 5).
DISCUSSION
The hypotensive prostaglandin analogues are a novel class of
intraocular-lowering medications used primarily for the treat-
ment of glaucoma. In recent years, prostaglandins have emerged
as the mainstay of treatment for ocular hypertension and/or
glaucoma. These include latanoprost, travoprost and bimato-
prost, which are ester or amide pro-drug analogues of the
prostaglandin F2-alpha.
The efficacy in lowering IOP of the three compounds is very
similar, and in a recent meta-analysis it was found that the
difference in decreasing IOP between the three products was
very small.
37 However, according to the literature, it has been
described that conjunctival hyperaemia occurs more frequently
with either bimatoprost and travoprost than with latano-
prost,
12 13 38 although neither systematic review nor meta-
analysis has been performed to date to assess this issue properly.
The reason for the reduction in hyperaemia caused by
latanoprost in the eye compared with bimatoprost and
travoprost likely lies in the latanoprost molecule and its
pharmacological receptor profile.
39
Table 1 Characteristics of 13 trials meeting criteria for inclusion in the meta-analysis
Source Design Intervention Duration of study No of patients
Percentage of patients with hyperaemia
Jadad
Score LAT BIMAT TRAVO
Gandolfi et al
24 Parallel LAT vs BIMAT 3 months LAT=113;
BIMAT=119
14.2 36.1 7
Dubiner et al
25 Parallel LAT vs BIMAT 1 month LAT=22; BIMAT=21 13.6 14.3 5
Noecker et al
26 Parallel LAT vs BIMAT 6 months LAT=136;
BIMAT=133
20.6 44.4 7
Walters et al
27 Parallel LAT vs BIMAT 1 month LAT=38; BIMAT=38 15.8 39.5 6
Konstas et al
28 Crossover LAT vs BIMAT 7 weeks each
treatment
LAT=21; BIMAT=21 28.6 71.4 5
Dirks et al
29 Parallel LAT vs BIMAT 3 months LAT=27; BIMAT=33 7.4 21.2 6
Konstas et al
30 Crossover LAT vs BIMAT 3 months each
treatment
LAT=123;
BIMAT=123
7.3 26 7
Netland et al
31 Parallel LAT vs TRAVO 12 months LAT=193;
TRAVO=402
27.6 44 6
Parrish et al
32 Parallel LAT vs TRAVO vs
BIMAT
3 months LAT=136;
BIMAT=136;
TRAVO=138
47.1 68.6 58 7
Parmaksiz et al
33 Parallel LAT vs TRAVO 9 months LAT=16; TRAVO=18 6.2 38.8 5
Chen et al
34 Parallel LAT vs TRAVO 3 months LAT=36; TRAVO=37 8.3 13.5 6
Garcia-Feijoo et al
35 Parallel LAT vs TRAVO 2 weeks LAT=30; TRAVO=32 3.3 6.2 5
Konstas et al
36 Crossover LAT vs TRAVO 8 weeks each
treatment
LAT=40; TRAVO=40 15 37.5 6
BIMAT, bimatoprost; LAT, latanoprost; TRAVO, travoprost.
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of conjunctival hyperaemia of three prostaglandin analogues on
the information reported in the international literature, as
conjunctival hyperaemia is a condition of concern, since local
side effects may have a negative affect on whether the patient
takes the drug as directed (compliance) and/or continues to use
the drug over time (persistency). Other local side effects such as
the change in iris colour and the development of darker and
longer eye lashes may also cause a decrease in treatment
compliance and persistency, so it will be necessary to explore
this issue in the future by conducting new studies.
The results of this meta-analysis show that the use of
latanoprost is associated with a lower incidence of conjunctival
hyperaemia. Arcieri et al
40 found that there was a significant
increase in hyperaemia scores in the latanoprost, bimatoprost
and travoprost groups 1 week after baseline. Hyperaemia scores
reached their peak 15 days after baseline and started to decrease
1 month after therapy was initiated. Thus, it is important to
point out that the conjunctival hyperaemia could decrease
during the use of prostaglandin analogues in daily medical
practice.
This meta-analysis may have some limitations. First, we
cannot fully exclude publication bias, because there were no
sufficient studies to detect asymmetry in a funnel plot, and we
did not perform a statistical test for the detection of publication
bias: these tests have a very low power in meta-analysis of a
small number of trials. In addition, we did not attempt to gain
access to unpublished results, and only publications written in
English were accepted. Second, clinical trials included in this
meta-analysis were undertaken in many different countries, so
we cannot eliminate location bias. Third, the studies included
were heterogeneous in terms of study population, length of each
study, number of patients of different studies, basal condition,
associated comorbidities and the way of evaluating conjunctival
hyperaemia. Access to individual level data could certainly have
improved the quality of adjustment as well as the precision of
estimates.
CONCLUSION
The results of this meta-analysis suggest that latanoprost is
associated with a lower incidence of conjunctival hyperaemia
versus the use of bimatoprost and travoprost in the treatment
of ocular hypertension and/or glaucoma. This information may
be useful for determining the optimal treatment strategy for
individual patients.
More research is needed to determine the incidence of
conjunctival hyperaemia after the use of prostaglandin analo-
gues in the mid and long term, as well as in real-world daily
medical practice.
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